Trial Profile
Impact of Eculizumab therapy on survival and liver outcome in patients with paroxysmal nocturnal hemoglobinuria and Budd Chiari syndrome
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Sep 2019
Price :
$35
*
At a glance
- Drugs Eculizumab (Primary)
- Indications Budd-Chiari syndrome; Paroxysmal nocturnal haemoglobinuria
- Focus Therapeutic Use
- 12 Sep 2019 New trial record